Date 01.08.2026
Auropharma
Timeframe : Day Chart
Long With Caution
(1) Compunded sales growth at just 2% (ttm)
(2) Versus PE growth 32% (ttm), same peroid
(3) Stagnant EPS year on year
(4) Stagnant sale growth from last 3 quarters
(5) Other income plays critical role in higher EPS
(6) Net profit to topline is very subdued
(7) Whereas, Sun pharma, Divis, Ajanta pharma, Abbott & zydus have 2X profitability w.r.t point number 6
Note*
(1) The U.S. generic sector experiences unrelenting price erosion driven by buying-consortium consolidations. This systematically eats away at basic profit margins
Regards,
Ankur
Auropharma
Timeframe : Day Chart
Long With Caution
(1) Compunded sales growth at just 2% (ttm)
(2) Versus PE growth 32% (ttm), same peroid
(3) Stagnant EPS year on year
(4) Stagnant sale growth from last 3 quarters
(5) Other income plays critical role in higher EPS
(6) Net profit to topline is very subdued
(7) Whereas, Sun pharma, Divis, Ajanta pharma, Abbott & zydus have 2X profitability w.r.t point number 6
Note*
(1) The U.S. generic sector experiences unrelenting price erosion driven by buying-consortium consolidations. This systematically eats away at basic profit margins
Regards,
Ankur
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.